via University of Southampton
Scientists from the Antibody and Vaccine group at the University of Southampton have discovered a way to transform antibody drugs previously developed to treat autoimmunity into antibodies with powerful anti-cancer activity through a simple molecular “switch”.
This work, published in the journal Cancer Cell, focuses on a molecule called CD40 which is present on the surface of immune cells and controls both autoimmunity and cancer. In autoimmunity, CD40 is thought to be over-stimulated, increasing the chance of the immune system attacking healthy tissues; whereas in cancer, CD40 is believed to be under-stimulated, enabling tumour cells to evade the immune system. Targeting of CD40 with antibody drugs is ongoing in therapeutic interventions for both diseases.
Accordingly, antibody drugs have been developed to either activate (agonists) or suppress (antagonists) the CD40 immune pathway. Researchers at the Centre for Cancer Immunology in Southampton, led by Professors Mark Cragg and Martin Glennie now reveal that an antagonist CD40 antibody can be transformed into an agonist by simply modifying the “constant” domain of the antibody. The antagonist-turned agonist “trick” was shown for three different antagonists, being driven by the hinge part of the constant domain that controls the flexibility of the antibody. One of these antibodies, was shown to be a “super”-agonist that could stimulate the immune system and cure cancer more effectively in preclinical models than the best CD40-targeting antibody currently in clinical trial.
“Being able to toggle between an autoimmune drug and a cancer medicine with a simple switch is really exciting.” said Dr Xiaojie Yu, first author of the study. “We gained a deeper understanding of the mechanism through which CD40 becomes activated, and eagerly look forward to applying this technology to more drug candidates.”
“Our findings build on a history of CD40 research here in Southampton and were surprising and exciting in equal measure,” said Professor Mark Cragg, senior author of the study. “Taking an antibody that suppresses the immune system and turning it on its head, to activate the immune system for cancer through a relatively simple process is unprecedented. More than that, the same approach could be used for other immune targets and we look forward to seeing testing this in the near future”.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Anti-cancer treatments
- Can an anti-seizure medicine lengthen the lifespan of patients suffering from rare brain cancer?
Gabapentin actually kept the tumour from expanding. Combining it with other glioblastoma therapies could stave off some of the cognitive decline we see in patients and perhaps extend their lives,’ ...
- My Reluctance to Use Marijuana During Cancer Treatment
Growing up, I thought that only “bad boys” used marijuana, but after my cancer diagnosis, my perception slowly changed.
- Research To Develop Use Of Spinal Cord Stimulation For Chemotherapy-related Pain And Cancer Treatment
Researchers at Johns Hopkins University School of Medicine say they have evidence from a new study in rats that spinal cord stimulation (SCS) may be useful in reducing chronic pain in people ...
- Certain Toxic Effects Higher With Newer Prostate Cancer Therapies
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Second-generation anti-androgens (AAs) for the treatment of prostate cancer are associated with an increased risk of ...
- Roche drives rival anti-TIGIT developers higher after cancer drug data
Anti-TIGIT drug developers rose on Friday in reaction to promising early-stage data for Roche's (RHHBY) experimental liver cancer drug tiragolumab.
Go deeper with Google Headlines on:
Anti-cancer treatments
[google_news title=”” keyword=”anti-cancer treatments” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
CD40
- Apexigen (APGN) to Get Acquired by Pyxis Oncology, Stock Up
The candidate is a humanized agonist antibody that targets and activates CD40 to stimulate an anti-tumor immune response. Sotigalimab is currently being evaluated in an investigator-initiated phase II ...
- HC Wainwright & Co. Reiterates Eledon Pharmaceuticals (ELDN) Buy Recommendation
Fintel reports that on May 26, 2023, HC Wainwright & Co. reiterated coverage of Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy recommendation. As of May 11, 2023, the average one-year price target ...
- New Approaches for the Treatment of Lupus Nephritis in the 21st Century
In contrast to the positive signal of CD28/B7 or CD40–CD40L, ligation of PD1 on lymphocytes inhibits B- and T-cell proliferation and cytokine synthesis. PD1 and PDL1 interactions are essential ...
- Pyxis Oncology to Acquire Apexigen
Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linkers, payloads and conjugation chemistries previously ...
- Soluble CD40 Ligand in Acute Coronary Syndromes
CD40 ligand is expressed on platelets and released from them on activation. We investigated the predictive value of soluble CD40 ligand as a marker for clinical outcome and the therapeutic effect ...
Go deeper with Google Headlines on:
CD40
[google_news title=”” keyword=”CD40″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]